Nasdaq · Healthcare
Medpace Holdings, Inc. (MEDP)
As-reported financials and recent SEC filings for Medpace Holdings, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.53B
Net income
$451.1M
Net margin
17.8%
Diluted EPS
$15.28
ROE
98.3%
P/E (TTM)
33.2×
Market cap
$15.05B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B |
| Gross profit | — | — | — | — | — |
| Operating income | $534.9M | $446.9M | $336.8M | $278.7M | $198.6M |
| Net income | $451.1M | $404.4M | $282.8M | $245.4M | $181.8M |
| Diluted EPS | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
32026-06-04
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-06-01
View on EDGAR →1442026-05-28
View on EDGAR →8-K2026-05-19
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →Go deeper on MEDP
Search Medpace Holdings, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.